UL Prospector
Prospector

CelluCap™ RL

  • Société:

    Tagra Biotechnologies Ltd.

  • INCI Name:

    Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate (and) Retinol (and) Cellulose Acetate Butyrate (and) Tricaprylin

CelluCap™ RL’s encapsulated Retinol is easily released upon mechanical pressure, such as a rubbing action. The single layer polymeric shell collapses and breaks down into invisible particles, but still retains the payload to continue and deliver over time. Until the moment of application, Retinol remains fresh and potent. Retinol is highly recognized as a very effective vitamin for anti-aging treatment due to its capacity to stimulate collagen production, accelerate cell reproduction and normalize skin keratinization. Its regular application significantly improves skin elasticity, smoothness, and softness, resulting in younger, clearer and healthier looking skin. Nevertheless, Retinol is highly sensitive to oxidation, degradation in the presence of air, sunlight, acidic conditions and heavy metals which results in decreased efficacy and formula discoloration. Tagra Biotechnologies overcomes these challenges with CelluCap™ RL. By delivering stabilized pure Retinol in a microencapsulation, Tagra helps to improve the performance and shelf life of the final formula.

Upgrade to Prospector Premium to view Compliance Highlights En savoir plus

Retailer Compliance Status

No retailer information is available at this time.

Regulatory & Advisory Status

Aucune information réglementaire n’est disponible pour l’instant.

Compliance information powered by UL's ChemADVISOR™ Regulatory Database.

Société

Tagra Biotechnologies, since its inception in 1998, focuses on developing and manufacturing microencapsulated ingredients such as actives, pigments, essential oils, UV filters, and highly water-soluble ingredients.

Tagra is the first to patent a unique innovative Release on Demand™ (RND™) Microencapsulation Technology. Tagra’s platform addresses industry challenges of stability, efficiency, and compatibility with other cosmetic and pharmaceutical formulation ingredients. The technology enables the masking, protecting, and releasing of more than 40 actives and pigments widely used in cosmetics and OTC preparations. Tagra’s microcapsules are friction released through consumer applications.

Tagra also owns and operates its own plant and state-of-the-art laboratory meeting all required regulations.

Documents du fournisseur

L'information donnée sur cette fiche technique a été donné à UL par le fournisseur de la matière. UL déploie des efforts considérables pour assurer l'exactitude de ces données. Cependant, UL n'assume aucune responsabilité pour les valeurs des données et vous encourage fortement de valider les données avant la sélection finale avec le fournisseur des matériaux.

Tagra Biotechnologies Ltd. vous présente la documentation dans les régions indiquées ci-dessous:

Où acheter

Tagra Biotechnologies Ltd.

Etes-vous un distributeur et intéressé d’apparaître sur cette page? Contactez-nous!